DEVAN COOPER MCALL: Open Payments
NPI 1598461527 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$909 in 79 payments from 12 companies in 2025. Trend: 2023 $800 · 2024 $1,564 · 2025 $909
Food & beverage: $909
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 31 | $212 |
| Novo Nordisk Inc | 17 | $178 |
| Sumitomo Pharma America, Inc. | 9 | $143 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $69 |
| Lilly USA, LLC | 4 | $67 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $56 |
| AstraZeneca Pharmaceuticals LP | 3 | $54 |
| ABBVIE INC. | 3 | $51 |
| GlaxoSmithKline, LLC. | 2 | $32 |
| Esperion Therapeutics, Inc. | 1 | $18 |
Products named: OTEZLA, GEMTESA, Wegovy, Kerendia, Ozempic, Rybelsus, REPATHA, AIRSUPRA.
Industry payments across AL — which companies pay providers there.
